Efficacy and safety observation of apatinib in treatment of advanced gastric cancer

Q4 Medicine 肿瘤研究与临床 Pub Date : 2019-12-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2019.12.005

Zhihui He, Jiangzheng Zeng, F. Huang, Junhua Lei

{"title":"Efficacy and safety observation of apatinib in treatment of advanced gastric cancer","authors":"Zhihui He, Jiangzheng Zeng, F. Huang, Junhua Lei","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.005","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effect and safety of apatinib in the treatment of advanced gastric cancer. \n \n \nMethods \nA total of 60 patients with advanced gastric cancer at the first Affiliated Hospital of Hainan Medical College from April 2015 to October 2018 were retrospectively analyzed, and all patients were divided into two groups according to the treatment method, each group of 30 cases. The control group was treated with conventional treatment, and the observation group was given the treatment of apatinib on the basis of the control group, and then the clinical curative effect and adverse reactions were compared between the two groups. \n \n \nResults \nThere were 2 cases (6.67%) of complete remission in the observation group, 14 cases (46.67%) of partial remission, 10 cases (33.33%) of stability and 4 cases (13.33%) of disease progression, and the total effective rate was 53.33% (16/30). The control group had no complete remission, 8 cases (26.67%) of partial remission, 11 cases (36.67%) of stability and 11 cases (36.67%) of disease progression, and the total effective rate was 26.67% (8/30). The difference of total effective rate between the two groups was statistically significant (χ 2 = 4.444, P = 0.035). There was no significant difference in the level of tumor marker carcinoembryonic antigen (CEA), carbohydrate antigen (CA)199, CA125, cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) between the two groups before and after treatment (all P > 0.05). The incidence of hand-foot syndrome and hypertension in the observation group was higher than that in the control group [73.33% (22/30) vs. 43.33% (13/30), H = 5.554, P = 0.018; 76.67% (23/30) vs. 46.67% (14/30), H = 5.711, P = 0.017]. The incidence of proteinuria, bone marrow suppression and the cardiac adverse reactions in the observation group was higher than that in the control group [63.33% (19/30) vs. 33.33% (10/30), H = 3.300, P = 0.069; 60.00%(18/30) vs. 36.67% (11/30), H = 5.455, P = 0.071; 53.33% (16/30) vs. 30.00% (9/30), H = 3.360, P = 0.067]. \n \n \nConclusion \nApatinib is effective in the treatment of advanced gastric cancer, but the occurrence of hand-foot syndrome and hypertension should be paid close attention during the treatment. \n \n \nKey words: \nStomach neoplasms; Tumor markers, biological; Molecular targeted therapy; Apatinib; Comparative effectiveness research; Adverse effects","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"814-817"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the effect and safety of apatinib in the treatment of advanced gastric cancer. Methods A total of 60 patients with advanced gastric cancer at the first Affiliated Hospital of Hainan Medical College from April 2015 to October 2018 were retrospectively analyzed, and all patients were divided into two groups according to the treatment method, each group of 30 cases. The control group was treated with conventional treatment, and the observation group was given the treatment of apatinib on the basis of the control group, and then the clinical curative effect and adverse reactions were compared between the two groups. Results There were 2 cases (6.67%) of complete remission in the observation group, 14 cases (46.67%) of partial remission, 10 cases (33.33%) of stability and 4 cases (13.33%) of disease progression, and the total effective rate was 53.33% (16/30). The control group had no complete remission, 8 cases (26.67%) of partial remission, 11 cases (36.67%) of stability and 11 cases (36.67%) of disease progression, and the total effective rate was 26.67% (8/30). The difference of total effective rate between the two groups was statistically significant (χ 2 = 4.444, P = 0.035). There was no significant difference in the level of tumor marker carcinoembryonic antigen (CEA), carbohydrate antigen (CA)199, CA125, cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) between the two groups before and after treatment (all P > 0.05). The incidence of hand-foot syndrome and hypertension in the observation group was higher than that in the control group [73.33% (22/30) vs. 43.33% (13/30), H = 5.554, P = 0.018; 76.67% (23/30) vs. 46.67% (14/30), H = 5.711, P = 0.017]. The incidence of proteinuria, bone marrow suppression and the cardiac adverse reactions in the observation group was higher than that in the control group [63.33% (19/30) vs. 33.33% (10/30), H = 3.300, P = 0.069; 60.00%(18/30) vs. 36.67% (11/30), H = 5.455, P = 0.071; 53.33% (16/30) vs. 30.00% (9/30), H = 3.360, P = 0.067]. Conclusion Apatinib is effective in the treatment of advanced gastric cancer, but the occurrence of hand-foot syndrome and hypertension should be paid close attention during the treatment. Key words: Stomach neoplasms; Tumor markers, biological; Molecular targeted therapy; Apatinib; Comparative effectiveness research; Adverse effects

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

阿帕替尼治疗晚期癌症的疗效及安全性观察

目的探讨阿帕替尼治疗晚期癌症的疗效和安全性。方法回顾性分析海南医学院第一附属医院2015年4月至2018年10月收治的60例晚期癌症患者，按治疗方法分为两组，每组30例。对照组采用常规治疗，观察组在对照组基础上给予阿帕替尼治疗，比较两组的临床疗效及不良反应。结果观察组完全缓解2例（6.67%），部分缓解14例（46.67%），病情稳定10例（33.33%），病情进展4例（13.33%），总有效率53.33%（16/30）。对照组无完全缓解，部分缓解8例（26.67%），病情稳定11例（36.67%），疾病进展11例（3667%），总有效率26.67%（8/30）。两组总有效率差异有统计学意义（χ2=4.444，P=0.035），细胞角蛋白19片段抗原21-1（CYFRA21-1）。观察组手足综合征和高血压的发生率高于对照组[73.33%（22/30）vs.43.33%（13/30），H=5.554，P=0.018；76.67%（23/30）vs.46.67%（14/30），H=5.711，P=0.017]，观察组骨髓抑制及心脏不良反应发生率均高于对照组[63.33%（19/30）vs.33.33%（10/30），H=3.300，P=0.069；60.00%（18/30）vs.36.67%（11/30），H=5.455，P=0.071；53.33%（16/30）vs.30.00%（9/30），P=3.360，P=0.067]，但手足综合征和高血压的发生在治疗过程中应引起高度重视。关键词：胃肿瘤；肿瘤标志物，生物学；分子靶向治疗；阿法替尼；比较有效性研究；不良影响

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.